Tiziana Life Sciences Raises 4 Million Grant for Groundbreaking Biotech Research in Oncology and Immunology

Tiziana Life Sciences plc, a pioneering UK-based biotechnology company specializing in the discovery and development of novel therapeutics for oncology and immunology, has successfully raised £4 million in its latest funding round. This significant investment is earmarked for advancing its clinical trials and accelerating the development of its promising lead compound, milciclib, which targets and inhibits specific cyclin-dependent kinases (CDK) involved in the regulation of cell division. Currently undergoing Phase II clinical trials, milciclib aims to provide new hope for patients suffering from thymic carcinoma who have previously undergone chemotherapy. Additionally, the funding will bolster Tiziana's efforts in the clinical development of foralumab, the only fully human engineered anti-human CD3 antibody in clinical trials. Foralumab holds immense potential for treating a spectrum of autoimmune and inflammatory diseases, including ulcerative colitis, multiple sclerosis, and type-1 diabetes (T1D), as well as conditions like psoriasis and rheumatoid arthritis. With this injection of capital, Tiziana Life Sciences is poised to accelerate its innovative research programs, ultimately bringing groundbreaking therapies to market that could revolutionize treatment options for patients with challenging health conditions. As the company continues to forge ahead in its mission, it remains committed to enhancing therapeutic outcomes and improving the quality of life for those impacted by debilitating diseases.